申请人:Lee Hong Boon
公开号:US20110212955A1
公开(公告)日:2011-09-01
The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R
1
represents aryl, Het
1
or C
1-6
alkyl, which latter group is optionally substituted by aryl or Het
2
; R
2a
and R
2b
together form C
3.8
n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C
1-4
alkyl, C(O)OH and C(O)O—C
1-4
, alkyl and which alkylene group is optionally interrupted by X
1
; R
3a
and R
3b
together form C
3-6 /7-alkylene, which alkylene group is
optionally substituted by one or more substituents selected from halo. C
1-4
alkyl, C(O)OH and C(O)O—C
1-4
alkyl, and which alkylene group is optionally interrupted by X
2
; X
1
and X
2
independently represent O, S, or NR
4
; R
4
represents, independently at each occurrence, H, C(O)OR
5
, C(O)R
6a
, C(O)N(R
6b
)R
6c
or C
1-6
, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het
3
or is substituted by a single C(O)OR
1a
group; R
4a
represents H or C
1-4
alkyl; R
5
represents aryl, Het
4
or C
1-6
alkyl optionally substituted by one or more substituents selected from halo, aryl and Het
5
; R
5e
to R
6d
independently represent H or R
5
; each aryl independently represents a C
6-10
carbocylic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C
1-6
alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR
7
, phenyl, napthyl and Het
6
) and OR
8
; R
7
and R
8
independently represent H, C
1-4
alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR
8a
substituent), Het
7
, phenyl or naphthyl; R
8a
represents H or C
1-4
alkyl; Het
1
to Het
7
independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulphur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C
1-6
alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR
9
and phenyl) and OR
10
; R
9
and R
10
independently represent H, C
1-4
alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A′ represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions.
本发明涉及一类新的罗萨明衍生物,其中在一种实施例中,化合物具有结构式(I)或其任何药学上可接受的盐或溶剂,其中:R1代表芳基,Het1或C1-6烷基,后一群基团可以被芳基或Het2取代;R2a和R2b共同形成C3.8n-烷基,该烷基可以被来自卤素,C1-4烷基,C(O)OH和C(O)O-C1-4烷基中的一个或多个取代基取代,并且该烷基可以被X1中断;R3a和R3b共同形成C3-6 / 7-烷基,该烷基可以被来自卤素,C1-4烷基,C(O)OH和C(O)O-C1-4烷基中的一个或多个取代基取代,并且该烷基可以被X2中断;X1和X2独立地表示O,S或NR4;R4在每次出现时独立地表示H,C(O)OR5,C(O)R6a,C(O)N(R6b)R6c或C1-6烷基,后一群基团可以被一个或多个来自卤素,芳基和Het3的取代基所取代,或被一个单独的C(O)OR1a基团所取代;R4a表示H或C1-4烷基;R5表示芳基,Het4或C1-6烷基,后一群基团可以被一个或多个来自卤素,芳基和Het5的取代基所取代;R5到R6d独立地表示H或R5;每个芳基独立地表示C6-10碳环芳基,该芳基可以包含一个或两个环,并且可以被一个或多个来自卤素,CN,C1-6烷基(后一群基团可以被一个或多个来自卤素,OR7,苯基,萘基和Het6的取代基所取代)和OR8的取代基所取代;R7和R8独立地表示H,C1-4烷基(可以被一个或多个卤素或单个苯基或C(O)OR8取代基所取代),Het7,苯基或萘基;R8a表示H或C1-4烷基;Het1到Het7独立地表示含有一个或多个来自氧,氮和/或硫的杂原子的5-至10元芳香,完全饱和或部分不饱和的杂环族群,该杂环族群可以包含一个或两个环,并且可以被一个或多个来自卤素,CN,C1-6烷基(后一群基团可以被一个或多个来自卤素,OR9和苯基的取代基所取代)和OR10的取代基所取代;R9和R10独立地表示H,C1-4烷基或苯基;除非另有说明,否则烷基可以被一个或多个卤素原子取代;A'表示药学上可接受的阴离子。还公开了制备和使用化合物以及制药组合物的方法。